Your shopping cart is currently empty

BI 703704, a soluble guanylate cyclase (sGC) activator, inhibits the progression of diabetic nephropathy in the ZSF1 rat [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | Inquiry | 3-6 months | 3-6 months | |
| 50 mg | Inquiry | 3-6 months | 3-6 months | |
| 100 mg | Inquiry | 3-6 months | 3-6 months |
| Description | BI 703704, a soluble guanylate cyclase (sGC) activator, inhibits the progression of diabetic nephropathy in the ZSF1 rat [1]. |
| In vivo | BI 703704 administered at dosages of 0.3 to 10 mg/kg through food intake daily for 15 weeks in fifty-eight male ZSF1 rats aged 12-13 weeks led to a dose-dependent reduction in urinary protein excretion (UPE) and a dose-dependent elevation in renal cGMP levels [1]. The compound effectively increases renal cGMP in a dose-responsive manner, thereby decelerating the progression of diabetic nephropathy under conditions of oxidative stress [1]. |
| Molecular Weight | 559.72 |
| Formula | C32H37N3O4S |
| Cas No. | 2740807-77-4 |
| Smiles | O(CC1=C(C)C=C(C(=O)N2CCCCC2)C=C1)C3=C(C=C(C)C=C3)C=4N=C(SC4)N5C[C@]6([C@@H](C(O)=O)[C@@](C5)(CC6)[H])[H] |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.